Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
HEY1-NCOA2 expression modulates chondrogenic differentiation and induces mesenchymal chondrosarcoma in mice
Miwa Tanaka, Mizuki Homme, Yasuyo Teramura, Kohei Kumegawa, Yukari Yamazaki, Kyoko Yamashita, Motomi Osato, Reo Maruyama, Takuro Nakamura
Miwa Tanaka, Mizuki Homme, Yasuyo Teramura, Kohei Kumegawa, Yukari Yamazaki, Kyoko Yamashita, Motomi Osato, Reo Maruyama, Takuro Nakamura
View: Text | PDF
Research Article Cell biology Oncology

HEY1-NCOA2 expression modulates chondrogenic differentiation and induces mesenchymal chondrosarcoma in mice

  • Text
  • PDF
Abstract

Mesenchymal chondrosarcoma affects adolescents and young adults, and most cases usually have the HEY1::NCOA2 fusion gene. However, the functional role of HEY1-NCOA2 in the development and progression of mesenchymal chondrosarcoma remains largely unknown. This study aimed to clarify the functional role of HEY1-NCOA2 in transformation of the cell of origin and induction of typical biphasic morphology of mesenchymal chondrosarcoma. We generated a mouse model for mesenchymal chondrosarcoma by introducing HEY1-NCOA2 into mouse embryonic superficial zone (eSZ) followed by subcutaneous transplantation into nude mice. HEY1-NCOA2 expression in eSZ cells successfully induced subcutaneous tumors in 68.9% of recipients, showing biphasic morphologies and expression of Sox9, a master regulator of chondrogenic differentiation. ChIP sequencing analyses indicated frequent interaction between HEY1-NCOA2 binding peaks and active enhancers. Runx2, which is important for differentiation and proliferation of the chondrocytic lineage, is invariably expressed in mouse mesenchymal chondrosarcoma, and interaction between HEY1-NCOA2 and Runx2 is observed using NCOA2 C-terminal domains. Although Runx2 knockout resulted in significant delay in tumor onset, it also induced aggressive growth of immature small round cells. Runx3, which is also expressed in mesenchymal chondrosarcoma and interacts with HEY1-NCOA2, replaced the DNA-binding property of Runx2 only in part. Treatment with the HDAC inhibitor panobinostat suppressed tumor growth both in vitro and in vivo, abrogating expression of genes downstream of HEY1-NCOA2 and Runx2. In conclusion, HEY1::NCOA2 expression modulates the transcriptional program in chondrogenic differentiation, affecting cartilage-specific transcription factor functions.

Authors

Miwa Tanaka, Mizuki Homme, Yasuyo Teramura, Kohei Kumegawa, Yukari Yamazaki, Kyoko Yamashita, Motomi Osato, Reo Maruyama, Takuro Nakamura

×

Figure 2

Gene expression profile of murine mesenchymal chondrosarcoma.

Options: View larger image (or click on image) Download as PowerPoint
Gene expression profile of murine mesenchymal chondrosarcoma.
(A) Gene s...
(A) Gene set enrichment analysis (GSEA) shows correlation of Notch signaling and hyaluronic acid binding pathways with genes involved in eSZ cells expressing HEY1::NCOA2. (B) Systematical analysis of the signaling pathways for 167 upregulated and 48 downregulated genes in mesenchymal chondrosarcoma by the IPA software. The diseases and disorders are listed according to their ranking scores. Blue rectangles indicate each P value. P values were calculated using Fischer’s exact test. (C) GSEA showing inverse and forward correlations between HEY1-NCOA2 knockdown in mouse mesenchymal chondrosarcoma and pediatric cancer markers and proteoglycans pathways, respectively. The P value was computed through the 2-sided permutation test (n = 1,000 randomizations) adjusted by the Benjamini-Hochberg procedure. (D) Principal component analysis for gene expression profiles of murine mesenchymal chondrosarcoma, Ewing sarcoma, alveolar soft part sarcoma, and synovial sarcoma. (E) GSEA shows enrichment of the Notch pathway and the signature for the regulation of osteoblast differentiation by Runx2 in mesenchymal chondrosarcoma. (F) Venn diagram showing upregulated genes in HEY1-NCOA2–expressing eSZ cells versus eSZ cells containing an empty vector or mesenchymal chondrosarcoma versus eSZ cells containing an empty vector. (G) qRT-PCR shows upregulated expression of Hey1, Hes1, and Bcl11b in mesenchymal chondrosarcoma cells. (H) Growth suppression of mesenchymal chondrosarcoma cells C24 by shRNA-mediated gene silencing of HEY1-NCOA2 in vitro. (I) qRT-PCR shows increased expression of HEY1, HES1, and BCL11B in human mesenchymal chondrosarcoma tissues. ASPS, alveolar soft part sarcoma; MCS, mesenchymal chondrosarcoma (n = 5); MLS, myxoid liposarcoma (n = 6); EWS, Ewing sarcoma (n = 6); OS, osteosarcoma (n = 5); SS, synovial sarcoma (n = 5). Statistical analyses in G and H were performed by 1-way ANOVA and in I were performed by 2-sided Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts